EP1237479A2 - Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l'infrarouge proche - Google Patents

Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l'infrarouge proche

Info

Publication number
EP1237479A2
EP1237479A2 EP00967472A EP00967472A EP1237479A2 EP 1237479 A2 EP1237479 A2 EP 1237479A2 EP 00967472 A EP00967472 A EP 00967472A EP 00967472 A EP00967472 A EP 00967472A EP 1237479 A2 EP1237479 A2 EP 1237479A2
Authority
EP
European Patent Office
Prior art keywords
skin
spectrum
disease
spectra
visible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00967472A
Other languages
German (de)
English (en)
Inventor
Laura M. Mcintosh
Michael Jackson
Henry H. Mantsch
James R. Mansfield
A. Neil Crowson
John W. P. Toole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of EP1237479A2 publication Critical patent/EP1237479A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems

Definitions

  • the present invention relates generally to the field of spectroscopy.
  • the present invention relates to a method for non-invasively diagnosing skin diseases using visible and near-infrared spectroscopy.
  • Skin cancer is the most common human cancer. In 1999, it is estimated that there will be 70000 new cases of skin cancer in Canada (Canadian Cancer Statistics: Toronto: National Cancer Institute of Canada, 1999) and more than 1 million new cases in the United States. The clinical diagnosis is often difficult since many benign skin diseases resemble malignancies upon visual examination. As a consequence, histopathological analysis of skin biopsies remains the standard for confirmation of a diagnosis. However, the decision must be made as to which and how many suspicious skin diseases to biopsy.
  • Visible/infrared (IR) spectroscopy may be that tool (Jackson et al, 1997, Biophys Chem 68:109- 125).
  • the IR spectrum is divided into three regions: near-IR (700-2500 nm), mid-IR (2500-50000 nm) and far-IR (beyond 50000 nm).
  • near-IR 700-2500 nm
  • mid-IR 2500-50000 nm
  • far-IR beyond 50000 nm
  • the near-IR region is often sub-divided into the short (680-1100 nm) and long (1100-2500 nm) near-IR wavelengths, based upon the technology required to analyze light in these wavelength regions.
  • the heme proteins oxy- and deoxyhemoglobin and myoglobin
  • cytochromes dominate the spectra, and their absorptions are indicative of regional blood flow and oxygen consumption.
  • Long wavelength near-IR absorptions arise from overtones and combination bands of the molecular vibrations of C-H, N-H and O-H groups. The absorption of near-IR light therefore provides information concerning tissue composition (i.e. lipids, proteins) and oxygen delivery and utilization.
  • Visible and near-IR light is brought from a spectrometer to the skin via a fiber optic cable.
  • the light penetrates the skin, and water, hemoglobin species, cytochromes, lipids and proteins absorb this light at specific frequencies.
  • the remaining light is scattered by the skin, with some light being scattered back to the fiber optic probe.
  • the light is collected by the probe and transmitted back to the spectrometer for analysis.
  • a plot of the amount of light absorbed at each wavelength (the spectrum) is computed. Measurements are rapid, non-destructive and non-invasive.
  • a method of diagnosing skin diseases comprising: providing a patient having a disease; emitting a beam of visible/near-IR light into a portion of the skin afflicted with the skin disease; collecting and analyzing reflected light from the beam, thereby producing a condition spectrum; emitting a beam of visible/near-IR light into a control skin portion of the patient which is not afflicted with the skin disease; collecting and analyzing reflected light from the beam, thereby producing a control spectrum; comparing the control spectrum and the condition spectrum; and identifying the skin disease based on said comparison.
  • a method comprising: a) providing a patient having a skin disease; b) emitting a beam of visible/near-IR light into a portion of the skin afflicted with the skin disease; c) collecting and analyzing reflected light from the beam, thereby producing a disease spectrum; d) emitting a beam of visible/near-IR light into a control skin portion of the patient which is not afflicted with the skin disease; e) collecting and analyzing reflected light from the beam, thereby producing a control spectrum; f) performing a biopsy on the portion of the skin afflicted with the skin disease; g) classifying the skin disease based on the biopsy; h) assigning the control spectrum and the disease spectrum to a skin disease group based on the classification; and i) creating a database by repeating steps (a) to (h).
  • Figure 2 shows paired t-test results comparing normal and skin lesion near-IR spectra.
  • the mean normalized spectra blue and red traces
  • the optical density scale refers to the spectra
  • the p-value scales correspond to the p-plot traces.
  • Figure 3 shows the difference visible/near-IR spectra from skin lesions. Difference spectra were obtained by subtracting each lesion-normal pairing for each group shown in Fig 3. Actinic keratoses (blue), BCC (red), actinic lentigines (green), dysplastic nevi (black), banal nevi (pink) and seborrheic keratoses (brown) are shown. The areas used for analysis of variance (ANOVA) are shaded over the spectra.
  • Figure 4 shows optimal classification regions of visible/near-IR spectra from skin lesions. Class average spectra are shown with the regions for optimal classification (GA-ORS) indicated in the darkly shaded regions and the regions that were significant by ANOVA indicated in the lightly shaded regions. Three optimal regions were selected for dysplastic vs. banal nevi (a), five regions for actinic keratoses vs. actinic lentigines (b), five regions for actinic keratoses vs. seborrheic keratoses (c) and four regions for BCC vs. seborrheic keratoses (d). No regions were significant by ANOVA for b and c.
  • a "skin condition” is a dermatological disorder that manifests as a rash, irritation or dry skin. Examples of skin conditions are psoriasis, hives, eczema, etc.
  • a “skin lesion” is a circumscribed abnormal area of the skin such as a tumor, nodule or papule.
  • a "skin disease” is any abnormal area of the skin caused by disease. Skin diseases include both skin conditions and skin lesions (but not injuries due to external insult such as cuts and burns).
  • Actinic keratoses are reddish, rough areas of damaged skin which are considered pre-malignant. A small percentage of these lesions develop into the malignant tumor, squamous cell carcinoma.
  • Base cell carcinoma or BCC refers to a slow-growing malignant epithelial neoplasm. This type of cancer in usually “cured” by surgical removal if caught early.
  • Actinic lentigines are small benign pigmented lesions often referred to as age or liver spots.
  • Plastic nevi refer to atypical moles which are considered to be pre-malignant or at greater risk of becoming malignant.
  • “Seborrheic keratoses” are common light brown to black skin growths that are benign.
  • Boal or benign nevi are common benign moles.
  • visible/near-IR spectra were recorded for a number of patients having skin lesions, as described below.
  • a spectrum was taken of an unaffected skin portion as a control from each patient.
  • a biopsy was also performed on the skin lesion and the results of the biopsy were used to assign the skin lesion to a specific category.
  • the disease spectra and the control spectra were then compared using statistical analysis as described below to detect wavelength regions of significant difference between the control spectra and the lesion spectra. These results were then grouped by skin lesion category based on the biopsy results.
  • the grouped spectra showed characteristic patterns in the differential spectra over a specific set of wavelengths. As a consequence, these differences can be used to identify or diagnose a skin disease by comparing the visible/near-IR spectrum of a control region to a spectrum taken of the region of interest.
  • the skin disease is diagnosed by emitting a beam of visible/near-IR light into a portion of the skin afflicted with the skin disease, and collecting and analyzing reflected light from the beam, thereby producing a spectrum of the diseased skin portion. The process is repeated for an unaffected region of skin, thereby providing a control spectrum. The control spectrum and the disease spectrum are then compared and the skin disease is identified based on the comparison.
  • the skin disease is selected from the group consisting of dysplastic melanocytic nevi; banal nevi; lentigines; actinic keratoses; seborrheic keratoses; basal cell carcinoma; and malignant melanoma.
  • the control spectrum and the disease spectrum may be compared at wavelengths corresponding to visible/near-IR absorption by oxyhemoglobin, deoxyhemoglobin, water, proteins, lipids or combinations thereof.
  • the wavelengths may be selected from the group consisting of: 518-598 nm; 618-698 nm; 718-798 nm; 918-998 nm; 1158-1238 nm; 1418-1498 nm; 1718-1798 nm; and combinations thereof.
  • spectra are taken of affected and control regions from several patients. A biopsy is then performed on each of the affected region, which is then used to positively identify the skin condition. The spectra are grouped according to skin condition, thereby forming a database.
  • control spectra and the disease spectra in each skin disease group in the database are then reduced to diagnostic wavelengths using a region selection algorithm. This algorithm is then used to analyze spectra from other skin portions so that the disease afflicting the skin portion can be identified based solely on the spectrum, without performing a biopsy.
  • Spectra were recorded in the 400-2500 nm range in 2 nm steps using a commercial spectrometer (Foss NIRSystems Model 6500) equipped with a bifurcated visible/near-IR fiber optic probe with a 7 mm active area.
  • Each reflectance spectrum was collected with a 10 nm slit width, and consisted of 32 scans, which were co-added to improve signal to noise.
  • the subject's skin and the end of the probe were cleansed with 70% alcohol.
  • the fiber optic probe was then positioned 0.5 mm from the measurement site by measuring with a micrometer. For all 195 cases, three (3) visible/near-IR spectra were taken from: 1) the lesion and 2) an area of normal appearing skin (the control site). Acquisition of each spectrum took 40 seconds.
  • spectra were grouped into one of six lesion categories: 1) actinic keratoses (33 cases, 99 spectra), 2) BCC (32 cases, 96 spectra), 3) dysplastic melanocytic nevi (13 cases, 39 spectra), 4) actinic lentigines (12 cases, 36 spectra), 5) banal common acquired nevi (22 cases, 19 intradermal and 3 compound nevi, 66 spectra) and 6) seborrheic keratoses (18 cases, 54 spectra). A total of 130 cases were thus included in the data set. The remaining 65 cases either did not fit into one of the above categories or the patient declined to have a biopsy after the measurements.
  • the histopathology was the "gold standard"
  • control spectra were found to lie within 2 standard deviations of the mean spectrum. Once again, control spectra that lay outside 2 standard deviations from the mean were associated with patient movement. Control spectra for each control site were then averaged, resulting in 130 control spectra.
  • LDA returns a value ranging between 0 (not belonging) and 1 (belonging) to each spectrum in a data set, indicating the membership in each class.
  • the values returned provide an indication of the likelihood of a spectrum belonging to each class.
  • Each spectrum is then allocated to the class to which it most belongs.
  • EXAMPLE IV - RESULTS The mean control (i.e. from normal skin) visible/near-IR spectrum is shown in Fig 1. Spectra are plotted showing the amount of light absorbed by the skin at each wavelength between 400-1840 nm. Each peak in the spectrum can be assigned to a specific compound found in the skin. Visually, strong absorption bands arising from O-H groups of water dominate the spectrum. However, much information is present in the weaker spectral features. For instance, the relatively strong absorption feature at -550 nm arises from hemoglobin species and provides information relating to the oxygenation status of tissues.
  • tissue oxygenation can be obtained from analysis of a weak absorption feature at 760 nm, arising from deoxyhemoglobin (Stranc et al, 1998, Br J Plast Surg 51:210-217).
  • Compositional information can be obtained from an analysis of two absorption bands between 1700-1800 nm associated with C-H groups of skin lipids.
  • a series of weak absorption bands arising from protein N-H groups is found in close proximity (usually overlapped by) the strong water absorptions.
  • tissue architecture/optical properties can be obtained from the spectra. Changes in tissue architecture/optical properties may affect the basic nature of the interaction of light with the tissue.
  • changes in the character of the epidermis may result in more scattering of light from the surface, reducing penetration of light into the skin in a wavelength dependant manner.
  • different tumor densities i.e. nodular vs. diffuse
  • Such phenomena would be manifest in spectra as changes in the slope of the spectral curves, especially in the 400-780 nm region.
  • Fig 2 mean normalized lesion spectra (red traces) and control spectra (blue traces) are shown overlaid on corresponding p-plots (black traces). Several areas of the resulting p-plot contained contiguous regions of statistically significant p-values (p ⁇ 0.05). Each lesion-normal comparison exhibited a slightly different p-plot, and therefore, a distinct pattern of significance.
  • Spectra from dysplastic nevi were significantly different from actinic keratoses, BCC, lentigines, banal nevi and seborrheic keratoses in a number of spectral regions.
  • BCC spectra were significantly different from banal nevi and seborrheic keratoses in three spectral regions, and seborrheic keratoses were different from lentigines in one spectral region.
  • Two class LDAs were performed on the following comparisons: 1 ) dysplastic vs. banal nevi, 2) dysplastic nevi vs. lentigines, 3) actinic keratoses vs. lentigines, 4) actinic keratoses vs. seborrheic keratoses, 5) BCC vs. seborrheic keratoses, 6) BCC vs. banal nevi and 7) dysplastic nevi vs. seborrheic keratoses.
  • optimal regions were identified by the GA-ORS algorithm.
  • Figure 4 shows the optimal regions for comparisons 1 , 3, 4 and 5.
  • LDA resulted in an overall accuracy of 97.7-72.4% compared to a clinical accuracy (by visual examination) of 100-78.0% and are shown in Table II.
  • the numbers in rows represent the histopathological classification, while results in columns represent the calculated classification.
  • the visible/near-IR spectra of skin presented here exhibit strong absorption bands from water and a number of weak, but consistent, absorption bands arising from oxy- and deoxy-hemoglobin, lipids and proteins.
  • visual examination of spectra did not show distinct differences in these spectral features that could be used to distinguish between spectra of skin diseases and healthy skin.
  • Univariate statistics were therefore applied in order to determine whether differences existed between skin lesions and healthy skin.
  • multivariate statistics were performed in an attempt to objectively classify spectra.
  • the region 718-798 nm contains the absorption of deoxyhemoglobin, while the region 918-998 nm contains a broad absorption associated with oxyhemoglobin.
  • the regions 1158-1238 nm and 1418- 1498 nm contain significant absorption bands from water, and possibly some contribution from protein N-H groups. Thus, it appears as if changes in the amount or structure of water in tissues occur between some types of lesion and control tissues.
  • spectral bands attributed primarily to C-H groups of skin lipids populate the region 1718-1798 nm. Significant differences between spectra in this region may imply differences in the amount or structure of skin lipids.
  • GA-LDA genetic algorithm guided linear discriminant analysis
  • the trained LDA algorithm can then be applied to unknown spectra, and the unknown spectra are partitioned into one of the clinical groupings based upon the spectral pattern found.
  • the advantage of LDA is that a combination of spectral regions (which perhaps on their own do not contain sufficient information to allow diagnosis), rather than individual regions, are used to achieve a diagnosis.
  • a prescribed accuracy typically > 90%
  • the linear discriminant analysis program takes the regions selected by the algorithm and identifies the hyperplane that optimally separates the sets of points corresponding to the spectral classes of interest.
  • class assignment of any given spectrum involves computing its distance from all class centroids (i.e. the representative class average spectrum) and allocating it to the class whose centroid is nearest.
  • class centroids i.e. the representative class average spectrum
  • a value ranging between 0 (not belonging) and 1 (belonging) is given, indicating the membership in each class, with the sum of the membership values for all classes being unity. The value returned therefore provides an indication of the likelihood of the spectrum belonging to each class.
  • GA-LDA was applied to difference spectra from benign and premalignant/ malignant lesion groups. Some of the more difficult visual diagnoses were successfully distinguished. All LDA comparisons save one resulted in an accuracy rate greater than 80%. Although the clinical (visual) diagnostic accuracy rate in this particular study was high (greater than 78%), other studies report clinical diagnostic accuracy rates of 42-65% (Pichter et al, 1991 , Br J Dermatol 125 (Suppl 38):93-97; Hallock and Lute, 1998, Plast Reconstr Surg 101 :1255-1261). The LDA results presented here compare favorably with such studies.
  • Spectral regions that contained diagnostic information were not the same as those identified by ANOVA, perhaps reflecting the fact that LDA uses combinations of regions (each of which on it's own may not show significant differences between classes) to enable diagnosis.
  • many spectral regions identified by GA-LDA suggest essentially the same biochemical basis for distinguishing between classes as by ANOVA. For example regions around 760 nm (deoxyhemoglobin), 900 nm (oxyhemoglobin) and 1200 nm (water) allowed discrimination between actinic keratoses and actinic lentigines.
  • regions around 760 nm (deoxyhemoglobin), 900 nm (oxyhemoglobin) and 1200 nm (water) allowed discrimination between actinic keratoses and actinic lentigines.
  • the biophysical basis underlying the diagnostic regions remains unclear.
  • dysplastic nevi exhibited a highly significant difference (p ⁇ 0.001 ) from almost all other lesion groups across most of the regions tested by ANOVA.
  • classification between dysplastic and banal nevi had the highest accuracy of all classifications (97.7%), with classification between dysplastic nevi and lentigines close behind (92%).
  • the accurate and early diagnosis of dysplastic nevi is a significant development in the recent emphasis placed on melanoma detection.
  • Visible/near-IR spectroscopy could form the basis of a clinical method to diagnose skin diseases. It is rapid (i.e. acquisition time of minutes), simple to perform and non-invasive. Measurements are accurate and reproducible. Collection of spectra causes little or no patient discomfort, does not alter the basic physiology of the skin, poses no hazard to the patient and does not interfere with any other standard clinical diagnostic practices. The test could be performed by a non-specialist and, therefore, might be a useful tool for pre-screening skin diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

L'invention concerne un outil non invasif pour effectuer le diagnostic de maladies de la peau, destiné à être utilisé en tant que dispositif clinique auxiliaire. L'étude sur laquelle est fondée cette invention avait pour but de déterminer si la spectroscopie dans le visible/infrarouge proche peut être exploité pour la caractérisation non invasive de maladies de la peau. Des spectres in vivo dans le visible et infrarouge proche (400-2500 nm) de tumeurs de la peau (kératoses séniles, carcinomes basocellulaires, naevus mélanocytaires banals communs acquis, naevus mélanocytaires dysplasiques, lentigines actiniques et kératoses séborrhéiques) ont été obtenus au moyen d'une sonde à fibre optique placée sur la peau. On a fait appel à des tests t jumelés, à une analyse de variance et à une analyse discriminatoire de mesures répétées pour déterminer s'il y avait des différences spectrales significatives et si les spectres pouvaient être classés selon le type de lésion. Les tests t jumelés ont montré des différences significatives (p<0,05) entre une peau normale et une peau présentant des lésions, dans plusieurs zones du spectre visible/infrarouge proche. En outre, des différences significatives ont été trouvées entre les groupes de lésions, par analyse de variance. L'analyse discriminatoire linéaire a permis de différencier des spectres résultant de lésions bénignes, en comparaison avec des lésions pré-malignes ou malignes. La spectroscopie dans le visible/infrarouge rouge constitue une technique non invasive prometteuse pour le diagnostic de maladies de la peau.
EP00967472A 1999-10-06 2000-10-05 Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l'infrarouge proche Withdrawn EP1237479A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15785799P 1999-10-06 1999-10-06
US157857P 1999-10-06
PCT/CA2000/001187 WO2001024699A2 (fr) 1999-10-06 2000-10-05 Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l'infrarouge proche

Publications (1)

Publication Number Publication Date
EP1237479A2 true EP1237479A2 (fr) 2002-09-11

Family

ID=22565569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00967472A Withdrawn EP1237479A2 (fr) 1999-10-06 2000-10-05 Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l'infrarouge proche

Country Status (4)

Country Link
EP (1) EP1237479A2 (fr)
AU (1) AU782431B2 (fr)
CA (1) CA2396883C (fr)
WO (1) WO2001024699A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346757A1 (de) * 2003-10-06 2005-05-12 Pe Diagnostik Gmbh Verfahren zur Klassifikation von Messwerten in der medizinischen und biochemischen Analytik
WO2010085954A1 (fr) * 2009-01-29 2010-08-05 Leo Pharma A/S Procédé de détermination de l'état d'un trouble cutané au moyen de la spectroscopie infrarouge proche
EP2490586B1 (fr) 2009-10-23 2014-11-12 Medespel Ltd Système d'examen de tissu non invasif
HRP20221528T1 (hr) * 2015-07-10 2023-02-17 Infectopharm Arzneimittel Und Consilium Gmbh Primjena kalijevog hidroksida u liječenju aktiničke keratoze
CA3117198A1 (fr) * 2018-10-23 2020-04-30 Aesthetics Biomedical, Inc. Procedes, dispositifs et systemes pour induire une regeneration de collagene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5016173A (en) * 1989-04-13 1991-05-14 Vanguard Imaging Ltd. Apparatus and method for monitoring visually accessible surfaces of the body
US6008889A (en) * 1997-04-16 1999-12-28 Zeng; Haishan Spectrometer system for diagnosis of skin disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0124699A2 *

Also Published As

Publication number Publication date
CA2396883C (fr) 2011-04-12
WO2001024699A8 (fr) 2001-10-04
AU7766200A (en) 2001-05-10
AU782431B2 (en) 2005-07-28
CA2396883A1 (fr) 2001-04-12
WO2001024699A2 (fr) 2001-04-12

Similar Documents

Publication Publication Date Title
McIntosh et al. Towards non-invasive screening of skin lesions by near-infrared spectroscopy
US7280866B1 (en) Non-invasive screening of skin diseases by visible/near-infrared spectroscopy
P. Santos et al. Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy
Zhao et al. Real-time Raman spectroscopy for automatic in vivo skin cancer detection: an independent validation
US7860554B2 (en) Visible-near infrared spectroscopy in burn injury assessment
Farina et al. Multispectral imaging approach in the diagnosis of cutaneous melanoma: potentiality and limits
Evers et al. Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies
US7570988B2 (en) Method for extraction of optical properties from diffuse reflectance spectra
EP1806093A2 (fr) Système de classification de détermination du sexe et de caractérisation de tissus
Hosking et al. Hyperspectral imaging in automated digital dermoscopy screening for melanoma
JP2013514520A (ja) ラマン分光法によるインビボでの組織の特徴付けのための装置および方法
EP1448092B1 (fr) Diaphanoscopie optique et spectroscopie par reflectance pour quantifier le risque de developper une maladie
WO2011009931A1 (fr) Imagerie infrarouge de mélanomes cutanés
Araújo et al. Finding reduced Raman spectroscopy fingerprint of skin samples for melanoma diagnosis through machine learning
McIntosh et al. Near-infrared spectroscopy for dermatological applications
Carpenter et al. Noninvasive optical spectroscopy for identification of non‐melanoma skin cancer: pilot study
de Oliveira Nunes et al. FT‐Raman spectroscopy study for skin cancer diagnosis
CA2396883C (fr) Diagnostic non invasif de maladies de la peau par spectroscopie dans le visible/l&#39;infrarouge proche
TWI755918B (zh) 傷口評估方法
Tosi et al. FTIR microspectroscopy of melanocytic skin lesions: a preliminary study
KR20140130191A (ko) Ftir 마이크로분광법으로 피부 발암의 공통적인 및 특이적인 특성화를 위한 분석 방법
Ahlgrimm-Siess et al. New diagnostics for melanoma detection: from artificial intelligence to RNA microarrays
Kanemura et al. Assessment of skin inflammation using near-infrared Raman spectroscopy combined with artificial intelligence analysis in an animal model
Hennessy et al. Segmentation of diffuse reflectance hyperspectral datasets with noise for detection of melanoma
Dahlstrand et al. Dybelius Ansson C, Memarzadeh K, Reistad N, Malmsjö M (2019) Extended-wavelength diffuse reflectance spectroscopy with a machine-learning method for in vivo tissue classification

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020503

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060503